



## <u>Technology Development Board</u>

<u>supports</u>

M/s Sapigen Biologix Private Limited, Hyderabad

<u>for</u>

"Development & Commercialization of two novel vaccines – Intranasal Covid-19 Vaccine" and "RTS, S Malaria Vaccine"





Technology Development Board, a statutory body of Department of Science & Technology, Government of India, has approved financial support of ₹100 Crores out of the total project cost estimated at ₹311.30 Crores to M/s Sapigen Biologix Private Limited, Hyderabad for development & commercialization of two novel vaccines - Intranasal Covid-19 Vaccine" and "RTS, S Malaria Vaccine".

The company aims to set up a state-of-the art cGMP facility in Bhubaneshwar, in compliance with latest global standards, for manufacturing Intranasal Covid-19 Vaccine and (RTS, S) Malaria Vaccine initially and later expand the product portfolio by adding other vaccines.







